AVITA MEDICAL INC (RCEL)
US05380C1027 - Common Stock
We assign a fundamental rating of 3 out of 10 to RCEL. RCEL was compared to 588 industry peers in the Biotechnology industry. RCEL may be in some trouble as it scores bad on both profitability and health. RCEL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
RCEL had negative earnings in the past year.
In the past year RCEL has reported a negative cash flow from operations.
1.2 Ratios
Looking at the Return On Assets, with a value of -31.69%, RCEL is in the better half of the industry, outperforming 70.82% of the companies in the same industry.
With a Return On Equity value of -72.11%, RCEL perfoms like the industry average, outperforming 55.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.69% | ||
| ROE | -72.11% | ||
| ROIC | N/A |
ROA(3y)-26.67%
ROA(5y)N/A
ROE(3y)-42.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RCEL has a better Gross Margin (84.92%) than 89.76% of its industry peers.
RCEL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RCEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCEL has been increased compared to 1 year ago.
Compared to 1 year ago, RCEL has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.40, we must say that RCEL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.40, RCEL is in line with its industry, outperforming 53.07% of the companies in the same industry.
A Debt/Equity ratio of 0.81 indicates that RCEL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.81, RCEL is not doing good in the industry: 76.11% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.4 |
ROIC/WACCN/A
WACC8.84%
2.3 Liquidity
A Current Ratio of 7.88 indicates that RCEL has no problem at all paying its short term obligations.
RCEL's Current ratio of 7.88 is fine compared to the rest of the industry. RCEL outperforms 72.35% of its industry peers.
A Quick Ratio of 7.46 indicates that RCEL has no problem at all paying its short term obligations.
RCEL has a Quick ratio of 7.46. This is in the better half of the industry: RCEL outperforms 70.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.88 | ||
| Quick Ratio | 7.46 |
3. Growth
3.1 Past
The earnings per share for RCEL have decreased strongly by -30.84% in the last year.
RCEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 45.64%.
RCEL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 52.07% yearly.
EPS 1Y (TTM)-30.84%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-27.27%
Revenue 1Y (TTM)45.64%
Revenue growth 3Y52.07%
Revenue growth 5YN/A
Revenue growth Q2Q50.05%
3.2 Future
The Earnings Per Share is expected to grow by 21.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, RCEL will show a very strong growth in Revenue. The Revenue will grow by 27.93% on average per year.
EPS Next Y19.54%
EPS Next 2Y36.71%
EPS Next 3Y32.99%
EPS Next 5Y21.01%
Revenue Next Year58.33%
Revenue Next 2Y48.73%
Revenue Next 3Y41.51%
Revenue Next 5Y27.93%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RCEL's earnings are expected to grow with 32.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y32.99%
5. Dividend
5.1 Amount
No dividends for RCEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVITA MEDICAL INC
NASDAQ:RCEL (5/3/2024, 7:15:02 PM)
After market: 8.76 +0.01 (+0.11%)8.75
+0.03 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap225.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.69% | ||
| ROE | -72.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.88 | ||
| Quick Ratio | 7.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-30.84%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y19.54%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)45.64%
Revenue growth 3Y52.07%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y